Media stories about WAVE Life Sciences (NASDAQ:WVE) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. WAVE Life Sciences earned a news sentiment score of 0.17 on Accern’s scale. Accern also assigned news stories about the company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an effect on the stock’s share price in the near future.
Shares of WAVE Life Sciences (WVE) opened at 16.85 on Friday. The firm has a 50-day moving average of $20.59 and a 200-day moving average of $25.18. WAVE Life Sciences has a 1-year low of $16.60 and a 1-year high of $40.15. The firm’s market capitalization is $467.03 million.
WAVE Life Sciences (NASDAQ:WVE) last released its quarterly earnings data on Wednesday, May 10th. The company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.77) by $0.12. The company had revenue of $0.68 million during the quarter, compared to analyst estimates of $0.80 million. WAVE Life Sciences had a negative net margin of 3,172.14% and a negative return on equity of 48.16%. On average, equities research analysts anticipate that WAVE Life Sciences will post ($3.25) EPS for the current fiscal year.
Several research analysts have weighed in on the stock. HC Wainwright reissued a “buy” rating on shares of WAVE Life Sciences in a report on Monday, March 27th. Jefferies Group LLC reiterated a “buy” rating and issued a $42.00 price objective on shares of WAVE Life Sciences in a research report on Wednesday, April 26th. JMP Securities restated an “outperform” rating and set a $40.00 price target on shares of WAVE Life Sciences in a research report on Friday, June 9th. Finally, ValuEngine downgraded shares of WAVE Life Sciences from a “hold” rating to a “sell” rating in a research report on Friday, June 16th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. WAVE Life Sciences has a consensus rating of “Buy” and an average target price of $42.00.
TRADEMARK VIOLATION WARNING: This report was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://sportsperspectives.com/2017/07/15/wave-life-sciences-wve-earns-coverage-optimism-rating-of-0-17.html.
In other news, insider Michael A. Panzara sold 7,414 shares of WAVE Life Sciences stock in a transaction on Wednesday, July 12th. The stock was sold at an average price of $16.67, for a total transaction of $123,591.38. Following the completion of the sale, the insider now owns 15,336 shares of the company’s stock, valued at $255,651.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 53.00% of the company’s stock.
About WAVE Life Sciences
WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Receive News & Ratings for WAVE Life Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.